Skip to content

Role of Pathyadi Churna and Baluka Sveda in patients of Rheumatoid arthrits vis-a-vis Amavata

A Comparative Control Clinical Evaluation of Pathyadi Churna and Baluka Sveda in patients of Rheumatoid Arthritis vis-a-vis Amavata - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064217
Enrollment
60
Registered
2024-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M068- Other specified rheumatoid arthritis Health Condition 2: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement Health Condition 3: M060- Rheumatoid arthritis without rheumatoid factor

Interventions

None listed

Sponsors

Department of Kayachikitsa
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged between 30-60 years of age of both the sex Diagnosed cases of Amavata based on symptoms and signs as described in Madava Nidana and EULAR criteria of RA Patients with H/O more than 1 year with established disease Sero-positive and sero-negative both cases will be included

Exclusion criteria

Exclusion criteria: 1 Patients below the age of 30 and above 60 years of age 2 Patients suffering from systemic disorders (like Diabetes Mellitus, Cardiac diseases, Pulmonary Tuberculosis, Essential Hypertension, SLE, Infectious Arthritis, Hypertrophic Arthropathy) 3 Pregnant & Lactating women 4 Patients with major complications are also excluded

Design outcomes

Primary

MeasureTime frame
Relief in signs and symptoms of the disease. The main signs and symptoms are follows: stiffnes lack of eating desire fever thirst lethargy swelling heaviness in body and joints indigestion Timepoint: 63 days with Follow up at 21 days interval

Secondary

MeasureTime frame
Changes in following: 1 On the basis of clinical sign and symptoms of the grading scale (0-3) 2 VAS scale 3 Ama strength grading scale 4 Assessment of severity of RA 5 Hematological investigations (CRP, RA factor,Anti CCP , CBC, LFT,RFT ,)Timepoint: 63 days with Follow up at 21 days interval

Countries

India

Contacts

Public ContactDr Ajai Kumar Pandey

Banaras Hindu University

drajaipandey@gmail.com9452827885

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026